SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases
Status:
NOT_YET_RECRUITING
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
The aim of this project is to evaluate whether the sequence of Trastuzumabpyrotinib and Nab-Paclitaxel in first line followed by SHR-A1811 in second line is superior to the sequence of SHR-A1811 in first line followed by Trastuzumabpyrotinib and Nab-Paclitaxel in second line for HER2 positive breast cancer brain metastases.
Phase:
PHASE2
Details
Lead Sponsor:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology